Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.63 |
| ▸ | ITK | Q08881 | 9/20 | 0.63 |
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20927092 | 0.90 | EGFR (0.59) | EGFRITKSYKBTK | |
| SCHEMBL12519793 | 0.86 | EGFR (0.83) | EGFRITK | |
| SCHEMBL12519661 | 0.77 | EGFR (1.00) | EGFRITKBTK | |
| SCHEMBL24486525 | 0.77 | EGFR (0.73) | EGFRITKSYKBTK | |
| SCHEMBL13166579 | 0.77 | EGFR (0.75) | EGFRITKSYKBTK | |
| SCHEMBL13165908 | 0.77 | EGFR (0.79) | EGFRITKBTK | |
| SCHEMBL656179 | 0.76 | SYK (0.69) | EGFRITKSYKBTK | |
| SCHEMBL29722547 | 0.75 | EGFR (0.78) | EGFRITKBTK | |
| SCHEMBL12519437 | 0.75 | EGFR (0.78) | EGFRITKBTK | |
| SCHEMBL13498252 | 0.74 | EGFR (0.70) | EGFRITKSYKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| US-20160130295-A1 | MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130295-A1 | MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM | RAD18, MVD, USP18 | EGFR 1683/4885ITK 2398/4885SYK 801/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | EGFR 176/4885ITK 352/4885SYK 494/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ITK 2697/4885SYK 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.